Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102

Ann Oncol. 2020 Jan;31(1):15-16. doi: 10.1016/j.annonc.2019.11.001.

Authors

P M Kasi¹, A Grothey²

Affiliations

¹ Division of Hematology, Oncology and Bone Marrow Transplantation, Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
² West Cancer Center and Research Institute, OneOncology, Germantown, Tennessee, USA. Electronic address: agrothey@westclinic.com.

PMID: 31912790
DOI: 10.1016/j.annonc.2019.11.001

No abstract available

Publication types

Editorial
Comment

MeSH terms

Colorectal Neoplasms*
Drug Combinations
Humans
Neutropenia*
Pyrrolidines
Thymine
Trifluridine
Uracil / analogs & derivatives

Substances

Drug Combinations
Pyrrolidines
trifluridine tipiracil drug combination
Uracil
tipiracil
Thymine
Trifluridine